Vernal keratoconjunctivitis : Fifteen months experience with 0.1% topical ophthalmic FK-506 ointment - 25/08/11
Abstract |
Rationale |
To determine a long-term response of VKC to 0.1% topical FK-506 treatment.
Methods |
Ten chronic cases (9 boys) of VKC were enrolled with mean ages of 9.12 ± 2.45 yrs. The mean duration of VKC was 3.97 ± 1.96 yrs. They were successful treated with 0.1% FK-506 ophthalmic ointment in our earlier report (4weeks). Frequencies of FK 506 were then decreased according to symptoms. They were followed monthly to every 2 months. Eye symptoms and side effect were monitored. Blood levels of FK506 were determined at 4 weeks and 6 months after initial treatment. CBC, renal and liver functions were obtained at baseline and every 6 months.
Results |
Six patients were able to discontinue the use of FK506 (with 1 day to 1 week intermittent use) whereas 4 patients require once daily treatment. There was a significant reduction tarsal papilla (from 1.09 ± 0.64 mm to 0.38 ± 0.39 mm, p=0.01). Blood FK506 levels were undetectable with normal laboratory results in all patients. Both patients and physician rated high preference for the treatment.
Conclusion |
The use of FK506 brought about remission of VKC in 6 patients during this 1 year observation period.
Le texte complet de cet article est disponible en PDF. | Funding: Self-funded |
Vol 113 - N° 2S
P. S218 - février 2004 Retour au numéro
Article précédent
- Relative efficacy of butterbur and mediator antagonists on the histamine and allergen cutaneous response
- P.C. Soutar, D.K.C. Lee, C.M. Jackson, B.J. Lipworth
- Ku-Shen (Sophora flavescens Ait), a single Chinese herb, abrogates airway hyperreactivity in a murine model of asthma
- M.C. Wen, C.K. Huang, K.D. Srivastava, T.F. Zhang, B. Schofield, H.A. Sampson, X.M. Li
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?